" class="no-js "lang="en-US"> Or Peles - Medtech Alert
Tuesday, September 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Or Peles

Or Peles

About Or Peles

An experienced leader with 20+ years of experience in managing technology, product and development organizations. Played a key role in one of Israel’s startup success stories, helping NICE Actimize grow from a 6 person company with no revenue to $300M+ revenue and 1,000 people. Proven track record of combining business, product and technical decisions to deliver working software that satisfies real customer needs.

Related Story

Appointments

 Nym Health Names Or Peles Senior Vice President of Research & Development | Pharmtech Focus

Nym Health Names Or Peles Senior Vice President of Research & Development

January 21 2022

Nym Health, a leader in autonomous medical coding, today announced that Or Peles has joined […]